CYTOSORBENTS CORP (CTSO)
US23283X2062 - Common Stock
Taking everything into account, CTSO scores 2 out of 10 in our fundamental rating. CTSO was compared to 192 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CTSO have multiple concerns. CTSO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CTSO had negative earnings in the past year.
CTSO had a negative operating cash flow in the past year.
CTSO had negative earnings in each of the past 5 years.
In the past 5 years CTSO always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -53.52%, CTSO is not doing good in the industry: 70.83% of the companies in the same industry are doing better.
CTSO has a Return On Equity of -122.47%. This is in the lower half of the industry: CTSO underperforms 74.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.52% | ||
| ROE | -122.47% | ||
| ROIC | N/A |
ROA(3y)-44.28%
ROA(5y)-42.39%
ROE(3y)-84.83%
ROE(5y)-165.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTSO has a Gross Margin of 61.63%. This is comparable to the rest of the industry: CTSO outperforms 59.38% of its industry peers.
CTSO's Gross Margin has declined in the last couple of years.
CTSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.52%
GM growth 5Y-1.58%
2. Health
2.1 Basic Checks
CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTSO has more shares outstanding
Compared to 5 years ago, CTSO has more shares outstanding
Compared to 1 year ago, CTSO has a worse debt to assets ratio.
2.2 Solvency
CTSO has an Altman-Z score of -7.51. This is a bad value and indicates that CTSO is not financially healthy and even has some risk of bankruptcy.
CTSO's Altman-Z score of -7.51 is on the low side compared to the rest of the industry. CTSO is outperformed by 75.00% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that CTSO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.11, CTSO perfoms like the industry average, outperforming 56.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.51 |
ROIC/WACCN/A
WACC10.04%
2.3 Liquidity
A Current Ratio of 1.77 indicates that CTSO should not have too much problems paying its short term obligations.
CTSO has a Current ratio of 1.77. This is in the lower half of the industry: CTSO underperforms 78.13% of its industry peers.
CTSO has a Quick Ratio of 1.51. This is a normal value and indicates that CTSO is financially healthy and should not expect problems in meeting its short term obligations.
CTSO has a Quick ratio of 1.51. This is in the lower half of the industry: CTSO underperforms 69.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 14.47% over the past year.
Looking at the last year, CTSO shows a small growth in Revenue. The Revenue has grown by 4.78% in the last year.
CTSO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.07% yearly.
EPS 1Y (TTM)14.47%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-550%
Revenue 1Y (TTM)4.78%
Revenue growth 3Y-3.93%
Revenue growth 5Y10.07%
Revenue growth Q2Q-7.69%
3.2 Future
The Earnings Per Share is expected to grow by 22.28% on average over the next years. This is a very strong growth
CTSO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.09% yearly.
EPS Next Y43.51%
EPS Next 2Y29.65%
EPS Next 3Y20.84%
EPS Next 5Y22.28%
Revenue Next Year9.11%
Revenue Next 2Y13.7%
Revenue Next 3Y12.32%
Revenue Next 5Y25.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CTSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTSO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CTSO's earnings are expected to grow with 20.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.65%
EPS Next 3Y20.84%
5. Dividend
5.1 Amount
No dividends for CTSO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYTOSORBENTS CORP
NASDAQ:CTSO (5/3/2024, 3:30:00 PM)
0.88
+0.06 (+7.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap45.94M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.52% | ||
| ROE | -122.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.63% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)14.47%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y43.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.78%
Revenue growth 3Y-3.93%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y